These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 33204149)

  • 1. Resistance and Overcoming Resistance in Breast Cancer.
    Luque-Bolivar A; Pérez-Mora E; Villegas VE; Rondón-Lagos M
    Breast Cancer (Dove Med Press); 2020; 12():211-229. PubMed ID: 33204149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics'.
    Mehmood S; Faheem M; Ismail H; Farhat SM; Ali M; Younis S; Asghar MN
    Front Mol Biosci; 2022; 9():783494. PubMed ID: 35495618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer under age 40: a different approach.
    Ribnikar D; Ribeiro JM; Pinto D; Sousa B; Pinto AC; Gomes E; Moser EC; Cardoso MJ; Cardoso F
    Curr Treat Options Oncol; 2015 Apr; 16(4):16. PubMed ID: 25796377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. circRNAs in drug resistance of breast cancer.
    Misir S; Yaman SO; Petrović N; Sumer C; Hepokur C; Aliyazicioglu Y
    Oncol Res; 2022; 30(4):157-172. PubMed ID: 37304411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies.
    Yang F; He Q; Dai X; Zhang X; Song D
    Front Pharmacol; 2023; 14():1143102. PubMed ID: 36909177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid Biopsy: A New Tool for Overcoming CDKi Resistance Mechanisms in Luminal Metastatic Breast Cancer.
    González-Conde M; Yañez-Gómez C; López-López R; Costa C
    J Pers Med; 2021 May; 11(5):. PubMed ID: 34068388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing therapeutic resistance in breast cancer: from the lncRNAs perspective.
    Peng L; Jiang J; Tang B; Nice EC; Zhang YY; Xie N
    Theranostics; 2020; 10(23):10360-10377. PubMed ID: 32929354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance.
    Lin X; Xiang H; Luo G
    Eur J Med Chem; 2020 Nov; 206():112689. PubMed ID: 32829249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer drug resistance: Decoding the roles of Hippo pathway crosstalk.
    Dehghanian F; Ghahnavieh LE; Nilchi AN; Khalilian S; Joonbakhsh R
    Gene; 2024 Jul; 916():148424. PubMed ID: 38588933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine treatment in breast cancer: Cure, resistance and beyond.
    Tryfonidis K; Zardavas D; Katzenellenbogen BS; Piccart M
    Cancer Treat Rev; 2016 Nov; 50():68-81. PubMed ID: 27643748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
    de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
    Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting resistance to endocrine therapy in breast cancer: It's time for epigenetic biomarkers (Review).
    Fontes-Sousa M; Amorim M; Salta S; Palma De Sousa S; Henrique R; Jerónimo C
    Oncol Rep; 2019 Mar; 41(3):1431-1438. PubMed ID: 30664168
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Rangel N; Sánchez IL; Valbuena DS; Rondón-Lagos M
    Breast Cancer (Dove Med Press); 2024; 16():127-139. PubMed ID: 38505863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Breast Cancer Stem Cells Traits and Drug Resistance.
    Zheng Q; Zhang M; Zhou F; Zhang L; Meng X
    Front Pharmacol; 2020; 11():599965. PubMed ID: 33584277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.
    Tufail M; Cui J; Wu C
    Am J Cancer Res; 2022; 12(7):2920-2949. PubMed ID: 35968356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circular RNAs: novel regulators of resistance to systemic treatments in breast cancer.
    Guo XQ; Hua YM
    Neoplasma; 2022 Sep; 69(5):1019-1028. PubMed ID: 35900318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer.
    Naeem M; Iqbal MO; Khan H; Ahmed MM; Farooq M; Aadil MM; Jamaludin MI; Hazafa A; Tsai WC
    Molecules; 2022 May; 27(11):. PubMed ID: 35684353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer.
    Sobhani N; Fassl A; Mondani G; Generali D; Otto T
    Cells; 2021 Feb; 10(2):. PubMed ID: 33535617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.